PharmaCyte Biotech (PMCB) Preferred Shares (2011 - 2023)

PharmaCyte Biotech (PMCB) posted quarterly Preferred Shares of $20.0 million for Q3 2023, up 3905.02% quarter-over-quarter from $500000.0 in Q3 2013.

PharmaCyte Biotech (PMCB) Preferred Shares (2011 - 2023) Analysis & Trends

PharmaCyte Biotech (PMCB) has reported Preferred Shares for 4 consecutive years, with $20.0 million the latest figure, recorded in Q3 2023.

In Q3 2023, Preferred Shares changed N/A year-over-year to $20.0 million; the TTM figure through Jul 2023 stood at $20.0 million (changed N/A YoY), while the FY2013 annual figure was $580000.0, changed 0.0% from the prior year.
Preferred Shares improved to $20.0 million in Q3 2023 per PMCB's latest filing, from $500000.0 in the prior quarter.
Across five years, Preferred Shares topped out at $20.0 million in Q3 2023 and bottomed at $20.0 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	PharmaCyte Biotech	4.38 Mn	4.38 Mn	-	-

Download Data